Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (NASDAQ: APYX) is a surgical aesthetics and advanced energy technology company whose news flow centers on its Helium Plasma Platform Technology products, including Renuvion, the AYON Body Contouring System, and J-Plasma. Company press releases focus on developments in the cosmetic surgery market, the hospital surgical market, and OEM relationships with other medical device manufacturers.
Investors and observers following APYX news will see regular updates on financial performance, such as quarterly and annual revenue results, preliminary unaudited revenue ranges, and segment-level trends in Surgical Aesthetics and OEM revenue. The company also issues guidance updates and discusses factors influencing its revenue mix, including the commercial rollout of AYON and demand for single-use handpieces and generators.
Another key category of Apyx Medical news involves product and regulatory milestones. Recent announcements describe FDA 510(k) clearances and submissions related to the AYON Body Contouring System, as well as international regulatory approvals like the Ministry of Food and Drug Safety clearance in South Korea for the Apyx One console and single-use handpieces. These items highlight how the company is expanding the indications and geographic reach of its platforms.
APYX news also covers capital markets and corporate actions, including proposed and completed public offerings of common stock under an effective Form S-3 shelf registration statement, as reported in 8-K filings and related press releases. Additional items include notices of investor conference participation, inducement equity awards under Nasdaq Listing Rule 5635(c)(4), and information about annual stockholder meetings and governance matters.
This news page aggregates these disclosures so readers can review Apyx Medical’s earnings releases, product launch updates, regulatory submissions, financing transactions, and investor events in one place.
Apyx Medical Corporation has secured a new five-year credit facility worth up to
Apyx Medical Corporation (NASDAQ: APYX) announced it will release its financial results for Q4 and fiscal year 2022 before the market opens on March 16th. Management will hold a conference call at 8:00 a.m. ET that same day to discuss these results and answer questions. Interested parties can access the call by dialing 877-407-8289 (international: 201-689-8341) using access code 13736530. The call will also be available via a live webcast. Apyx Medical specializes in advanced energy technology, particularly in helium plasma products marketed as Renuvion and J-Plasma for cosmetic and surgical applications.
Apyx Medical Corporation (NASDAQ:APYX) announced that its Renuvion neck laxity procedure will be featured on 'The Balancing Act' talk show on Lifetime on February 13, 2023, at 7:30 am ET/PT. The segment will showcase a minimally invasive neck procedure performed by Dr. Charles J. Galanis, highlighting its effectiveness in reducing sagging skin. Renuvion is the only FDA-cleared product for addressing neck and chin skin laxity, offering patients minimal downtime and cost-effectiveness. The segment will also re-run on February 21, 2023, with additional broadcasts throughout the year.
Apyx Medical Corporation (NASDAQ:APYX) has submitted a 510(k) premarket notification to the U.S. FDA for its Renuvion APR Handpiece, aiming to expand its use for coagulating subcutaneous soft tissues after liposuction. Supported by a clinical study and extensive evidence, the submission indicates that no new risks are associated with Renuvion when used post-liposuction. CEO Charlie Goodwin expressed optimism about receiving the FDA clearance, which may alleviate existing limitations outlined in the Medical Device Safety Communication.
Apyx Medical Corporation (NASDAQ: APYX) has launched the Apyx One Console, an advanced energy system now available to U.S. medical professionals. This multi-functional generator integrates Renuvion technology with monopolar and bipolar energy capabilities. Key features include adaptive touch screens, cloud connectivity, and a four-year warranty. Designed in collaboration with leading physicians, the Apyx One Console aims to enhance user experience and provides an upgrade option for existing customers. This product reinforces Apyx's commitment to innovation in the cosmetic surgery market.
Apyx Medical Corporation (NASDAQ:APYX) reported preliminary revenue results for Q4 and full year 2022, revealing a total revenue range of $12.1 to $12.5 million for Q4, a decline of 28% to 26% year-over-year. For the full year, revenue ranged from $44.0 to $44.4 million, declining by 9% to 8% year-over-year. The Advanced Energy segment showed significant declines of 33% to 30% in Q4 and 15% to 14% for the full year, while OEM revenue grew 12% in Q4 and 37% for the year. Despite challenges, the company plans for over 35% growth in 2023 driven by regulatory objectives.
Apyx Medical Corporation (NASDAQ: APYX) announces the launch of its inaugural direct-to-consumer campaign, #ThisIsMe, aimed at promoting its Renuvion technology for minimally invasive procedures. The campaign features national digital advertising and social media initiatives targeting consumers seeking aesthetic improvements. This campaign follows recent FDA clearances for Renuvion, specifically for treating loose skin on the chin and neck. The marketing efforts are designed to enhance brand awareness and highlight the technology's unique benefits, positioning Renuvion as a leader in cosmetic procedures.
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in the Piper Sandler 34th Annual Healthcare Conference on November 30 at 11:00 a.m. ET, held at the Lotte New York Palace. Management will engage in a fireside chat, accessible via a live audio webcast on the Company's investor relations website.
Apyx Medical specializes in advanced energy technologies, notably its Helium Plasma Technology branded as Renuvion® for cosmetic and J-Plasma® for surgical markets, offering innovative solutions for tissue management.
Apyx Medical Corporation (NASDAQ: APYX) reported third-quarter 2022 results, revealing total revenue of $9.1 million, down 23% year-over-year. Advanced Energy revenue fell 31% to $7.1 million, while OEM revenue rose 34% to $2.0 million. The company recorded a net loss of $5.8 million, worsening from $4.2 million in Q3 2021. Due to ongoing disruptions from an FDA Safety Communication, Apyx revised its 2022 revenue guidance to a range of $44.8 million to $47.9 million, reflecting a potential decline of 8% to 1%. The management emphasized efforts to engage customers and secure new regulatory clearances.
Apyx Medical Corporation (NASDAQ:APYX) will release its third quarter financial results for fiscal year 2022 before the market opens on November 10th. A conference call, scheduled for 8:00 a.m. ET on the same day, will discuss the quarterly results and include a question and answer session. Interested participants can join via phone or listen to a live webcast through the company’s Investor Relations webpage. A replay of the call will be available for two weeks post-event.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
